Advertisement

Topics

New data reinforces clinical basis for switching to Sandoz biosimilar medicines

02:10 EST 14 Nov 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Novartis International AG / New data reinforces clinical basis for switching to Sandoz biosimilar medicines . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "New data reinforces clinical basis for switching to Sandoz biosimilar medicines"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...